Table 1 Cohort description and numbers.
From: Genetic associations with clozapine-induced myocarditis in patients with schizophrenia
Cases | Controls | |
|---|---|---|
Number | 42 | 67 |
Sample type | ||
Fresh blood/saliva/stored blood/tissue | 20/11/6/5 | 61/6/0/0 |
Age at clozapine initiation | ||
Mean age (years) ± SD | 37 ± 12 | 35 ± 11 |
Reported ethnicity | ||
European/other/unknown | 36/2/4 | 57/7/3 |
Outcome fatal | 24% (10/42) | — |
Sex (% male) | 71% (30/42) | 81% (54/67) |
Clinical factors | ||
Smoking—Y/N/Unknown | 29/7/6 | 49/18/0 |
Alcohol abuse—Y/N/Unknown | 10/25/7 | 9/46/12 |
Illicit drug use—Y/N/Unknown | 8/27/7 | 12/46/9 |
Valproate use—Y/N/Unknown | 12/26/4 | 9/58/0 |
BMI kg/m2 ± SD | 31.7 ± 6.8 (n = 30) | 27.8 ± 6.5 (n = 54) |
Cumulative clozapine dose—days 1–9 | ||
Mean (mg) ± SD | 751 ± 222 (n = 35) | 691 ± 289 (n = 62) |
Genetic analyses—QC pass ratea | ||
1. Genome-wide SNP association | 79% (33/42) | 93% (62/67) |
2. Rare variants/gene-level analysis | 71% (30/42) | 81% (54/67) |
3. Targeted short-read HLA typing | 93% (33/42) | 96% (62/67) |
4. Long-read HLA typing/phasing | 71% (30/42) | 90% (60/67) |
